Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer’s disease

Original article Hemimegalencephaly: foetal tauopathy with mTOR hyperactivation and neuronal lipidosis

“…Tau over-expression is also reported many years following traumatic contusions of the brain [22]. Phosphorylated tau can now even be demonstrated and measured in cerebrospinal fluid of adults with normal pressure hydrocephalus and in dementia tauopathies as a clinical marker of prognosis for dementia and gait impairment [23,37]. m mT TO OR R Hyperactivated mTOR has been identified in HME previously [1,9,10,20] and follows the pattern of tau expression with numerous dysmorphic cells exhibiting phospho-4E-BP1 and phospho-ribosomal S6 protein expression, whereas the contralateral hemisphere does not exhibit these mTOR biomarkers.…”

Methods for the Specific Detection and Quantitation of Amyloid-β Oligomers in Cerebrospinal Fluid

“…Luminex platforms have the advantages of simultaneous analyses of several biomarkers in one run, reduction of human error, potential of reduced reagent costs, and a modest reduction of sample volume when compared to classical ELISA [31]. The authors found that the BAN50 antibody based assay detected A␤ oligomers, but demonstrated also sA␤PP␣ fragment sensitivity, probably due to the N-terminal epitope of BAN50.…”

Targeting Emotion Circuits with Deep Brain Stimulation in Refractory Anorexia Nervosa

“…At the current stage of development, no multiplex immunoassaybased approaches that target 410 analytes have proved sufficiently sensitive to detect beta-amyloid and tau in CSF at the level achieved when optimizing conditions to simultaneously measure these analytes (Kang et al, 2012). Mass spectrometric-based assays offer an unbiased discovery approach (Craft et al, 2013); studies are underway with the same CSF ADNI samples allowing for a unique contrast to the multiplex immunoassay approach.…”